Skip to main content
TipRanks
Go Ultimate75% OFF

Spago Nanomedical AB (SPAGO) AI Stock Analysis

1 Followers
SE:SPAGO

Spago Nanomedical AB

(Nasdaq OMX AB:SPAGO)

Select Model
Rating:40Underperform
Price Target:SEK 0.04â–²(4.88% Upside)
Action:reiterated
Date:11/13/26

The overall score of 40 reflects a very high-risk, pre-revenue biotechnology company. The most significant factor is the extremely weak financial performance, characterized by negligible revenue and a dangerously high cash burn rate that threatens the company's survival without new funding. This is compounded by a persistently bearish technical trend, with the stock price in a clear downtrend below all key moving averages. The debt-free balance sheet provides a small buffer, but it is rapidly eroding.

Positive Factors
Debt-Free Balance SheetA debt-free balance sheet reduces refinancing and interest-rate exposure, preserving financial flexibility while the company advances its pipeline. Although equity has declined, the absence of reported debt avoids an additional fixed claim on resources and may simplify future capital allocation.
Negative Factors
Minimal and Declining RevenueRevenue remains negligible relative to the company’s development needs and has recently declined, showing that commercial traction is not yet established. This leaves Spago dependent on future product development and financing rather than recurring operating revenue to support its business.

Spago Nanomedical AB (SPAGO) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:SPAGO-63.39%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 33.21M
Dividend Yield
―
Average Volume (3M)
1.00M
Price to Earnings (P/E)
-1.0
Beta (1Y)
1.34
Revenue Growth
-97.52%
EPS Growth
31.31%
Country
Sweden
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Spago Nanomedical AB Business Overview & Revenue Model

Company Description

Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gado...

How the Company Makes Money

Spago Nanomedical AB is primarily a development-stage company. null

Spago Nanomedical AB Financial Statement Overview

Summary

Financial health is critically weak. The income statement shows virtually no revenue ($26K TTM) and massive operating losses, while cash flow is deeply negative (-$25.6M TTM operating cash flow) indicating rapid cash burn. The balance sheet is the only relative bright spot due to zero debt, but equity is eroding quickly. This is a pre-revenue company with unsustainable operations.

Income Statement

8Very Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue26.00K437.00K1.91M1.20M1.05M660.00K
Gross Profit-14.23M-19.38M-12.36M-23.28M-15.60M-16.78M
EBITDA-26.99M-26.39M-33.40M-42.22M-38.73M-38.69M
Net Income-24.40M-26.55M-32.51M-42.22M-39.31M-39.08M
Balance Sheet
Total Assets31.20M36.68M39.58M52.98M205.95M191.62M
Cash, Cash Equivalents and Short-Term Investments24.52M29.67M32.47M45.22M62.10M52.46M
Total Debt000000
Total Liabilities6.12M5.94M6.35M11.67M8.80M6.81M
Stockholders Equity25.07M30.75M33.23M41.32M197.16M184.81M
Cash Flow
Free Cash Flow-9.44M-28.53M-34.90M-45.06M-42.02M-40.20M
Operating Cash Flow-25.59M-28.30M-34.67M-44.91M-38.19M-35.57M
Investing Cash Flow-443.00K633.00K-230.00K-506.00K-3.83M-4.63M
Financing Cash Flow39.29M24.87M22.15M28.53M51.66M64.21M

Spago Nanomedical AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.04

Price Trends

50DMA0.08Negative
100DMA0.10Negative
200DMA0.11Negative

Market Momentum

MACD-0.01Negative
RSI32.41Neutral
STOCH32.46Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPAGO, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 32.41 is Neutral, neither overbought nor oversold. The STOCH value of 32.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPAGO.

Spago Nanomedical AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:SPAGO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 360.89M1.9063.09%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:IMMUSE:IMMU48NeutralSEK 217.58M-1.96-19.14%――13.06%
SE:XSPRAYSE:XSPRAY43NeutralSEK 596.31M-2.96-25.14%――40.78%
SE:BIOVIC.BSE:BIOVIC.B41NeutralSEK 86.64M-1.21-75.51%―56.06%63.95%
SE:SPAGOSE:SPAGO40UnderperformSEK 33.21M-1.03-87.37%―-97.52%31.31%
SE:FLUOSE:FLUO40UnderperformSEK 482.30M-6.55―――-23.57%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SE:SPAGOSE:BIOVIC.BSE:XSPRAYSE:IMMUSE:CANTASE:FLUODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:SPAGO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:SPAGOSpago Nanomedical AB0.04-0.05-56.84%
SE:BIOVIC.BBiovica International AB Class B0.30-0.27-47.18%
SE:XSPRAYXspray Pharma AB10.18-13.96-57.83%
SE:IMMUImmunicum AB3.50-1.49-29.79%
SE:CANTACantargia AB1.29-1.94-60.03%
SE:FLUOFluoGuide A/S29.50-8.50-22.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026